Biodesix, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has designated the Nodify CDT®? Test as an Advanced Diagnostic Laboratory Test (ADLT) effective June 30, 2023. Obtaining ADLT status is a recognition that the Nodify CDT test meets the stringent criteria established under the Protecting Access to Medicare Act of 2014 (PAMA).

ADLT status is reserved for innovative tests with Medicare coverage that provide new clinical diagnostic information that cannot be obtained from any other test or combination of tests. The payment amount for the Nodify CDT tests as established by the Medicare Administration Contractor is $649. The Nodify CDT test is used in combination with the Nodify XL2®?

test, previously awarded ADLT status on May 17, 2019, in Nodify Lung®? Nodule Risk Assessment Testing. These tests are designed to help physicians assess the risk of malignancy of pulmonary nodules to identify and prioritize high risk nodules for intervention while avoiding unnecessary invasive procedures on benign nodules.